Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 03, 2021 1:03pm
108 Views
Post# 33114837

RE:RE:RE:RE:RE:A case for voting out Gary Littlejohn

RE:RE:RE:RE:RE:A case for voting out Gary Littlejohn

I have a very practical question. Let's accept the company went through a reset in 2019-20. Let's say for the past 12 months they've been engaging with markets with an offering in the back of their mind. They picked up 4 institutions. Of course the price tag matters, of course what you have to sell matters, but is that a reasonable outcome from 12 months work? If you assume they were starting from a very poor baseline. Another assumption of mine is that for different reasons both R&D programs aren't/weren't ideal programs to sell. I have no experience in this area so I'm just looking for others with experience of these types of processes.


palinc2000 wrote: Since they seem to be willing to add another Board member with the skillsets required for capital markets for the US and Canadian markets then why not make it easier for them by voting Gary out,,? Why add to the number od Directors?

 

qwerty22 wrote:

Personally I don't want to send any more messages. I think this process was the message, it seems to me they took it seriously. I don't think there is any alternative but to allow them to execute their strategy. Seems to me they aren't playing games, they are serious people.

 

stockman75 wrote: Agree...In addition I think it holds the entire board accountable by sending a message. If you don't have significant money at risk and your interest is just marginally aligned then the long term share holders will help find a board that is 110% aligned and fully competent in all areas. Nothing personal just pragmatic business decision. Board has done a fantastic job on many fronts but some of the slight of hand on the share offering and pummeling long term holders is not acceptable. 

 

 





<< Previous
Bullboard Posts
Next >>